Infertility

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Retrieved on: 
Tuesday, January 16, 2024
Development, Agreement, Patient, Infection, Ceftriaxone, Infertility, Social work, Science, Gonorrhea, STI, Administration, Pelvic inflammatory disease, Vaccination, Bill, Risk, Education, Bacteria, Neisseria gonorrhoeae, Disease, BMBF, Doctor of Philosophy, HIV, Human services, Vaccine, Chronic pain, DHSC, OMV

The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.

Key Points: 
  • The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.
  • Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.
  • Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
  • “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections.

David Adamson, MD, Founder & CEO, ARC Fertility, Co-Authors Groundbreaking Study on Global Fertility Trends, Publishes in Oxford University Press Journal Human Reproduction Update

Retrieved on: 
Tuesday, January 16, 2024
Women, Parenting, Baby, Maternity, LGBTQ+, Practice Management, Family, Other Health, Health, Consumer, Fertility, ARC, Research, Infertility, Oxford University Press, Child, Literature, ART, Human, Birth control

Published in Human Reproduction Update, the findings address the critical issues surrounding declining fertility rates and their profound societal implications.

Key Points: 
  • Published in Human Reproduction Update, the findings address the critical issues surrounding declining fertility rates and their profound societal implications.
  • “As a leader in reproductive health, ARC Fertility is committed to addressing these challenges for employers and healthcare decision-makers and advocating for family-friendly policies worldwide.”
    Authored by international leaders in fertility research, the study highlights the evolving landscape of global fertility.
  • The study notes that half of the countries worldwide exhibit fertility rates below replacement levels, leading to demographic changes with far-reaching consequences.
  • Improvements in Fertility Care: The study highlights major advances in fertility care since the 1990s, significantly improving family-building opportunities.

Poised for a New Era of Wealth Management, Newly Independent Firm - Steadmont Advisors - Joins Forces with Dynasty Financial Partners to Deepen Client Services for the “Millionaire Next Door”

Retrieved on: 
Tuesday, January 16, 2024
Banking, Asset Management, Professional Services, Finance, Diamond, Troy University, RIA, Research, Merrill (company), University of Alabama, Infertility, Wachovia Securities, Credit analyst, Partner, ADV, Partnership, Lawyer, SouthTrust, Financial plan, Business, Commercial, Fidelity, Communication, Loss, Longevity, University, Webcast, Retirement, College, Financial adviser

Veteran financial advisors Taylor Hart, Mimi Dunn, and Amy Drinkard announced today that they have engaged Dynasty Financial Partners and Fidelity to launch a newly independent firm called Steadmont Advisors.

Key Points: 
  • Veteran financial advisors Taylor Hart, Mimi Dunn, and Amy Drinkard announced today that they have engaged Dynasty Financial Partners and Fidelity to launch a newly independent firm called Steadmont Advisors.
  • “We ultimately decided to join the Dynasty Network after years of conversations and due diligence in the space.
  • Taylor Hart, CFP®, CPFA®, serves as the President, Founding Partner, and a Client Advisor at Steadmont Advisors in Birmingham, AL.
  • Mimi Dunn, AWMA, from Birmingham, Alabama, serves as a Founding Partner, Chief Compliance Officer, and Client Advisor at Steadmont Advisors.

Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes

Retrieved on: 
Tuesday, January 16, 2024
Women, Medical Supplies, Oncology, General Health, Health, Medical Devices, Health Technology, Consumer, Ageing, Diabetes, Mortality, Woman, Death, Infertility, Sadness, Multimedia, Sustainable Development Goals, UN, Walking, Democratic republic, Stroke, Pain, Risk, Safety, COVID-19, HOLX, Emotion, Congo, United Nations, Infection, United, Gallup, Birth control

The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.

Key Points: 
  • The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.
  • The Index also shows that more women are sad, angry and worried now than at the height of the pandemic.
  • The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide.
  • Investing in women’s health not only benefits individual women, but also their families, communities and economies.”
    Key findings from this year’s Index:
    Testing for major health conditions remains low.

PherDal, the First and Only Sterile At-Home Insemination Kit, Awarded FDA Clearance; Now Accepting Pre-Orders

Retrieved on: 
Tuesday, January 16, 2024
Fertility, Infertility, Science, Insemination, LSI, Kit, Genomics, Conference, IVI, Femtech, FDA

DIXON, Ill., Jan. 16, 2024 /PRNewswire-PRWeb/ -- PherDal Fertility Science, Inc., creators of the first and only sterile, at-home insemination kit, is now accepting pre-orders of its intravaginal insemination (IVI) device, following FDA class II clearance. Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.

Key Points: 
  • Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.
  • Rooted in science, the PherDal Kit is the first and only to combine the sterile environment of the fertility clinic with the at-home capabilities of insemination.
  • Each PherDal Kit includes three (3) sterile syringes and three (3) sterile collection cups to make at-home insemination as sterile, safe and accessible as possible.
  • My husband, a mechanical engineer, and I invented the PherDal Kit, which successfully conceived our daughter with the second use.

Utah Fertility Center, an Ivy Fertility Clinic, Hires Dr. C. Matthew Peterson

Retrieved on: 
Friday, January 12, 2024
Nursing, Women, Genetics, Family, Other Health, Managed Care, Health, Consumer, Pharmaceutical, Patient, Research, Infertility, MD, Gynaecology, Brigham Young University, University, Spencer Kimball, Bachelor of Science, Ovarian cancer, University of Miami, Obstetrics, Physician, Birth control

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed C. Matthew Peterson, MD, to its team of physicians at Utah Fertility Center.

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed C. Matthew Peterson, MD, to its team of physicians at Utah Fertility Center.
  • Dr. Peterson is a board certified reproductive endocrinologist and infertility specialist.
  • “We are thrilled to welcome Dr. Peterson to Utah Fertility Center,” said Dierdre Conway, MD, practice director at Utah Fertility Center.
  • “I look forward to working alongside the compassionate individuals at Utah Fertility Center and Ivy Fertility,” said Dr. Peterson.

Cell Cryopreservation Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Biotechnology, Health, Medical Devices, Conditional sentence, Cryopreservation, Regenerative medicine, Cell, Research, Infertility, B cell, IVF, Risk, Tissue engineering, COVID-19, Sigma-Aldrich, Biobank, Stem cell, Prevalence

The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The increased demand for cost-effective cryopreservation medium has stemmed from increased research & development (R&D) activities to create advanced medicines.
  • For example, Merck KGaA's Sigma Aldrich brand provides frozen media solutions for stem cell applications while ensuring optimal recovery and cell survival, thus, propelling the cryopreservation market growth.
  • Additionally, developments in freezing media formulation and cryopreservation techniques, as well as leveraging cryopreservation freezing media applications in fields such as tissue engineering, cellular treatment, and stem cell research, have driven the market at a substantial rate.

New CCRM Fertility Location Opens in Jersey City, NJ

Retrieved on: 
Thursday, January 11, 2024
Patient, Fertility, MD, Infertility, IVF, University Medical Center, Johns Hopkins, University, Johns Hopkins Hospital, IRMS, IUI, York Street, NYU Langone Health, Birth control

JERSEY CITY, N.J., Jan. 11, 2024 /PRNewswire/ -- CCRM Fertility is opening a new clinic location in Jersey City to provide patients with greater access to its full array of fertility treatments and services in New Jersey. This now totals eight locations in New Jersey, which became part of the CCRM network when IRMS was acquired in June 2022. All existing IRMS locations will be rebranded to CCRM Fertility by 2025.

Key Points: 
  • JERSEY CITY, N.J., Jan. 11, 2024 /PRNewswire/ -- CCRM Fertility is opening a new clinic location in Jersey City to provide patients with greater access to its full array of fertility treatments and services in New Jersey.
  • The new, state-of-the-art Jersey City location will be led by Dr. Stephanie Marshall Thompson, MD and Dr. Serena H. Chen, MD .
  • "We are thrilled to open another location in the Tri-State Area," said CEO CCRM Fertility Bob LaGalia.
  • "I'm excited to expand CCRM further and bring top-tier fertility care to patients in Jersey City," said Dr. Thompson.

Kindbody Opens in Walnut Creek; Marks Four Years of Serving Patients and Employers with Transformative Reproductive Healthcare in the San Francisco Bay Area

Retrieved on: 
Tuesday, January 9, 2024
Silicon, Northwestern University, Patient, UCSF, Fertility, Infertility, IVF, REI, University, Gynaecology, Biomedical engineering, Obstetrics and gynaecology, San Francisco General Hospital, Hospital, Obstetrics, Parent, Georgia Tech, El Camino Real, Nursing

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, today announced the opening of Kindbody East Bay, its state-of-the-art clinic and IVF lab at 1700 N. Main Street in Walnut Creek, CA. The announcement comes at a time of extraordinary growth for the company which owns and operates 34 clinics nationwide, including a state-of-the-art fertility clinic and IVF lab in downtown San Francisco at 88 Sutter Street and a Silicon Valley location at 4756 El Camino Real in Los Altos. Kindbody East Bay was built to meet the growing demand for comprehensive fertility and family-building benefits that cover the full spectrum of reproductive care by Bay Area employers. The clinic is led by Dr. Geraldine Ekpo, a fertility specialist who is board-certified in both reproductive endocrinology and obstetrics and gynecology.

Key Points: 
  • Kindbody East Bay was built to meet the growing demand for comprehensive fertility and family-building benefits that cover the full spectrum of reproductive care by Bay Area employers.
  • The opening of Kindbody East Bay follows four years of serving employers and patients throughout the San Francisco Bay Area.
  • Dr. Ekpo is currently accepting new patients at the East Bay location and will continue to serve patients in San Francisco.
  • Employers who wish to learn more about how Kindbody delivers the best patient experience and outcomes while reducing healthcare costs can contact [email protected] .

Paterna Biosciences Announces Renowned Reproductive Biology Scientist Dr. Kyle Orwig as Co-Founder

Retrieved on: 
Monday, January 8, 2024
Biotechnology, General Health, Health, Other Health, Transplant, Paterna, Research, IVF, Male, Infertility, Reproduction, Fertility, University, UPMC Magee-Womens Hospital, Knowledge, Spermatogenesis, Obstetrics, Gynaecology, Birth control

Paterna Biosciences , a ground-breaking innovator in biotechnology and reproductive health, is pleased to announce Dr. Kyle Orwig has joined the company as a co-founder.

Key Points: 
  • Paterna Biosciences , a ground-breaking innovator in biotechnology and reproductive health, is pleased to announce Dr. Kyle Orwig has joined the company as a co-founder.
  • In addition to his co-founder role, Orwig is currently professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh.
  • Paterna Biosciences CEO Ed Rowland said, "Paterna Biosciences is thrilled to welcome Kyle Orwig to our team.
  • "I am honored and excited to join the exceptional team at Paterna Biosciences, many of them longtime colleagues," said Orwig.